Biomerieux SA operates in the Diagnostic substances sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Biomerieux SA with three other
pharmaceutical manufacturers in Europe:
Hikma Pharmaceuticals PLC
of the United Kingdom
sales of £1.45 billion [US$1.88 billion]
of which 40%
was Injectable Pharmaceuticals),
H. Lundbeck A/S
(15.63 billion Danish Kroner [US$2.35 billion]
of which 19%
was Other Pharmaceuticals), and
Stada Arzneimittel AG
based in Germany
(2.14 billion Euro [US$2.39 billion]
of which 60%
Biomerieux SA reported sales of 2.10 billion Euro (US$2.35 billion)
December of 2016.
increase of 7.1%
versus 2015, when the company's sales were 1.96 billion Euro.
Sales at Biomerieux SA have increased during each of the previous five years
(and since 2011, sales have increased a total of 47%).
Sales of Biofire Defense saw an increase
that was more than double the company's growth rate: sales were up
41.9% in 2016, from
24.80 million Euro to 35.20 million Euro.
Not all segments of Biomerieux SA experienced an increase in sales in 2016:
sales of Co-Development Program fell 5.9% to 6.40 million Euro.
(However, this segment's sales were only a very small portion of the company's overall sales).